The study indicated that the efficacy of IC inhibitors as cancer immunotherapy in CRC might improve by the addition of more than one IC inhibitor, with a consideration of higher instead of lower IFNγ expression levels [33]. This evidence concerns the gene IFNG and colorectal carcinoma.